Business Wire

ADVA extends GNSS assurance software to protect third-party timing receivers from cyberattacks

14.4.2022 10:00:00 EEST | Business Wire | Press release

Share

ADVA (FSE: ADV) today extended its Ensemble Sync Director GNSS assurance software to integrate any third-party vendor’s GNSS receiver observables at scale. A key pillar of ADVA’s aPNT+ technology, Ensemble Sync Director is now vendor-agnostic, providing defense-in-depth, resilient and assured PNT for more customers than ever before. Ensemble Sync Director can now transparently show and analyze GNSS observables from third-party receivers in even the largest deployments. This is key as synchronization based on satellite signals is vulnerable to failure, interference and cyberthreats, and so network operators urgently need to protect their critical timing with continuous monitoring and assurance. Now, they have the power to remotely detect issues with GNSS receivers from any vendor, helping to maintain high-quality timing performance, avoid disruptions and reduce operating costs.

“The number of GNSS devices in use is growing by the day, with many networks now relying on hundreds or even thousands of receivers. At the same time, the risks to satellite-based timing have never been greater, including the rising threat of jamming and spoofing attacks. By extending our GNSS assurance application capabilities beyond our own timing equipment, we’re empowering many more customers to protect their mission-critical synchronization in new or deployed infrastructure,” said Gil Biran, GM of Oscilloquartz, ADVA. “Our Ensemble Sync Director, with comprehensive GNSS assurance for both resilient and assured PNT, provides a simple, scalable and highly cost-efficient way to harness our unique experience and expertise in managing a huge number of GNSS-dependent network elements.”

ADVA’s Oscilloquartz GNSS assurance solution for integrating third-party receiver data is an extension of its Sync Director application, part of the Ensemble Controller network management platform. It offers centralized in-service monitoring and analysis of GNSS status and reliability as well as AI/ML-based prediction and prevention of obstruction, jamming and spoofing. Using topology and timing chain mapping, Ensemble Sync Director displays the entire timing network infrastructure in a user-intuitive graphical format. ADVA’s GNSS assurance capabilities are aligned with the goals of the DHS Resilient PNT Conformance Framework and future IEEE P1952 Resilient PNT Standard to protect critical infrastructure. Available from ADVA Professional Services, the new solution is ideal for network operators in telecoms, power utilities, financial trading, data centers and more, who need to ensure robust, reliable and resilient GNSS timing. It also offers significant value to system integrator vendors looking to add vital GNSS protection capabilities to their synchronization portfolio.

“People are increasingly aware of the risk factors affecting GNSS-reliant systems, as well as the heavy price that disruption can bring. Whether they are addressing PNT regulations or responding to the precarious geopolitical situation, more and more network operators are looking to take urgent action to safeguard their timing architectures with resilient and assured PNT capabilities. That’s why we’re extending our GNSS assurance software with real-time monitoring to integrate third-party timing receiver data and enable more customers to proactively protect their critical infrastructure,” commented Michael Port, VP of product line management at ADVA. “Scalable and easy to implement, our new offering adds instant value. What’s more, Ensemble Sync Director supports open integration, enabling end-to-end vendor-agnostic sync and timing network management.”

Further information is available in these slides: https://adva.li/third-party-gnss-assurance-slides.


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release

Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye